Premium
Extension of the mutational and clinical spectrum of SOX2 related disorders: Description of six new cases and a novel association with suprasellar teratoma
Author(s) -
Blackburn Patrick R.,
ChaconCamacho Oscar F.,
OrtizGonzález Xilma R.,
Reyes Mariana,
LopezUriarte Graciela A.,
Zarei Shabnam,
Bhoj Elizabeth J.,
PerezSolorzano Sofia,
Vaubel Rachael A.,
Murphree Marine I.,
Nava Jessica,
CortesGonzalez Vianney,
Parisi Joseph E.,
VillanuevaMendoza Cristina,
TiradoTorres Iris G.,
Li Dong,
Klee Eric W.,
Pichurin Pavel N.,
Zenteno Juan C.
Publication year - 2018
Publication title -
american journal of medical genetics part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 112
eISSN - 1552-4833
pISSN - 1552-4825
DOI - 10.1002/ajmg.a.40644
Subject(s) - anophthalmia , sox2 , context (archaeology) , biology , autism , microphthalmia , phenotype , genetics , pathology , medicine , transcription factor , gene , paleontology , psychiatry
SOX2 is a transcription factor that is essential for maintenance of pluripotency and has several conserved roles in early embryonic development. Heterozygous loss‐of‐function variants in SOX2 are identified in approximately 40% of all cases of bilateral anophthalmia/micropthalmia (A/M). Increasingly SOX2 mutation‐positive patients without major eye findings, but with a range of other developmental disorders including autism, mild to moderate intellectual disability with or without structural brain changes, esophageal atresia, urogenital anomalies, and endocrinopathy are being reported, suggesting that the clinical phenotype associated with SOX2 loss is much broader than previously appreciated. In this report we describe six new cases, four of which carry novel pathogenic SOX2 variants. Four cases presented with bilateral anophthalmia in addition to extraocular involvement. Another individual presented with only unilateral anophthalmia. One individual did not have any eye findings but presented with a suprasellar teratoma in infancy and was found to have the recurrent c.70del20 mutation in SOX2 (c.70_89del, p.Asn24Argfs*65). This is this first time this tumor type has been reported in the context of a de novo SOX2 mutation. Notably, individuals with hypothalamic hamartomas and slow‐growing hypothalamo‐pituitary tumors have been reported previously, but it is still unclear how SOX2 loss contributes to their formation.